Related Experiment Video
Updated: May 21, 2026
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Percutaneous Coronary Intervention Outcomes in Patients With Inflammatory Bowel Disease: A Comprehensive Review of
Faiza Aman Jajja1, Vikash Fnu2, Omar Alkasabrah1
1From the Department of Internal Medicine, New York Medical College/Landmark Medical Center, Woonsocket, RI.
Insights
Patients with inflammatory bowel disease (IBD) face a 30-40% higher risk of major adverse cardiovascular events after percutaneous coronary intervention. Managing IBD patients requires balancing antiplatelet therapy and immunosuppression risks.
Area of Science:
- Cardiology
- Gastroenterology
- Immunology
Background:
- Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is increasingly viewed as a systemic inflammatory disorder.
- IBD is associated with accelerated atherosclerosis and elevated cardiovascular disease (CVD) risk.
- Patients with IBD undergoing percutaneous coronary intervention (PCI) may be younger with fewer traditional CVD risk factors but face increased procedural risks.
Purpose of the Study:
- To review the pathophysiologic links between chronic intestinal inflammation and coronary artery disease (CAD).
- To assess the short- and long-term risks of adverse cardiovascular outcomes following PCI in IBD patients.
- To highlight management challenges in this patient population.
Main Methods:
- Comprehensive literature review of cohort studies and pathophysiological research.
- Analysis of evidence connecting intestinal inflammation mechanisms to CAD.
- Evaluation of outcomes data for IBD patients post-PCI.
Main Results:
- A 30-40% relative risk increase in major adverse cardiovascular events (MACE) observed in IBD patients post-PCI compared to controls.
- Key pathophysiologic links include endothelial dysfunction, hypercoagulability, immune activation, and loss of intestinal-vascular barrier integrity.
- Increased risks of myocardial infarction and heart failure are noted in the short to long term.
Conclusions:
- IBD patients have a significantly elevated risk of adverse cardiovascular outcomes after PCI.
- Management requires careful consideration of dual antiplatelet therapy (balancing bleeding risk) and immunosuppressive therapies (cardiovascular effects).
- Further research is needed to optimize cardiovascular care for IBD patients.
Abstract:
Inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis, is being increasingly recognized as a systemic inflammatory condition with a link to accelerated atherosclerosis and increased cardiovascular risk. Patients with inflammatory bowel disease are often younger and have fewer classical risk factors for coronary artery disease at the time of percutaneous coronary intervention, but there is an increasing body of evidence for an increased risk of adverse outcomes following the procedure. This review discusses the pathophysiologic connections between chronic intestinal inflammation and coronary artery disease, with special reference to endothelial dysfunction, hypercoagulability, immune activation, and the loss of the intestinal-vascular barrier in relation to unstable plaques and impaired vascular healing. A comprehensive review of the current literature, including cohort studies and pathophysiological research, was undertaken to assess the risk of short- and long-term outcomes following percutaneous coronary intervention in this group of patients. The current evidence clearly indicates that there is a 30-40% relative risk increase of major adverse cardiovascular events, including myocardial infarction and heart failure, in the short to long term compared to controls. The challenges in management include the difficulty in balancing dual antiplatelet therapy with increased gastrointestinal bleeding risk and the cardiovascular consequences of immunosuppressive therapy.
Related Concept Videos
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:26Inflammatory Bowel Disease I: Introduction